- Home
- RIV vs XFOR Comparison
RIV vs XFOR Comparison
Compare RIV & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIV | XFOR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.3M | 407.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RIV | XFOR |
|---|---|---|
| Price | $11.46 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.20 |
| AVG Volume (30 Days) | 86.0K | ★ 579.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,263.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.11 | $0.17 |
| 52 Week High | $12.56 | $6.63 |
Technical Indicators
Market Signals| Indicator | RIV | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 24.34 | 66.58 |
| Support Level | $11.02 | $3.38 |
| Resistance Level | $12.18 | $4.53 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.06 | 0.15 |
| Stochastic Oscillator | 9.54 | 75.42 |
Price Performance
Historical ComparisonAbout RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.